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Abstract Fibrillins are large extracellular glycoproteins
that form the principal component of microfibrils. These
perform a vital structural function in the extracellular
matrix of many tissues. Fibrillins have also been implicated
in mediating a number of protein–protein interactions,
some of which may be significant in regulating growth
factors such as transforming growth factor b. Here we
present the backbone and side-chain 1H, 13C and 15N
assignments for a 19 kDa protein fragment derived from
the N-terminus of human fibrillin-1, encompassing four
domains in total. These domains include the second and
third epidermal growth factor-like (EGF) domains, the first
hybrid domain (hyb1), and the first calcium-binding EGF
domain of fibrillin-1. This region of fibrillin-1 is of par-
ticular interest as the hyb1 domain has been suggested to
play a role in microfibril assembly, as well as several other
protein–protein interactions.
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Biological context
Fibrillins assemble into oligomeric microfibrils, 10–12 nm
in diameter, with a ‘‘beads on a string’’ appearance when
viewed by rotary shadowing electron microscopy (Hand-
ford 2000; Lu et al. 2006). However, the protein interac-
tions that drive assembly of microfibrils are poorly
understood. Pulse-chase studies of chick aortae demon-
strated that, after secretion, fibrillin was rapidly incorpo-
rated into disulphide-bonded aggregates (Reinhardt et al.
2000). While the identity of the intermolecular disulphide
bonds driving this aggregation remains unclear, it has been
demonstrated that the fibrillin hyb1 domain contains an
additional cysteine residue (Cys 204), which is present as a
free thiol when expressed in cell culture (Reinhardt et al.
2000). This additional cysteine is also highly conserved
(Robertson et al. 2011), and so presents a good candidate
for intermolecular disulphide bond formation.
The hyb1 domain of fibrillin-1, and its flanking domains,
have also been implicated in a number of protein–protein
interactions, particularly interactions with latent trans-
forming growth factor b (TGFb) binding proteins (LTBPs)
and fibulins (Isogai et al. 2003; Massam-Wu et al. 2010; Ono
et al. 2009). The interaction with LTBPs is of particular
interest, as it may sequester TGFb to microfibrils, and could
play a role in disease progression in Marfan syndrome
(MFS), where fibrillin haploinsufficiency has been associ-
ated with over-activation of TGFb (Neptune et al. 2003).
Inhibiting TGFb signalling in mouse models of MFS has
been shown to restore near normal development in many
tissues (Cohn et al. 2007; Habashi et al. 2006, 2011; Ng et al.
2004), demonstrating a biologically significant connection
between fibrillin and TGFb signalling.
Here we present backbone and side-chain assignments
for the EGF2-EGF3-hyb1-cbEGF1 domains of human
fibrillin-1 (FBN1e2cb1) (Fig. 1a), derived from a protein
fragment of 177 amino acids, from Ser 113 to Glu 287.
These assignments will be used to investigate the structure
and dynamics of this four-domain fibrillin-1 fragment, and
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also determine potential binding sites for LTBPs and other
molecules.
Methods and experiments
Protein expression and purification was carried out in a
similar fashion to that described previously (Knott et al.
1996) but with modifications. The protein fragment was
expressed in Escherichia coli BL21 cells transformed with
a pQE-30 (Qiagen) expression vector and pREP4 plasmid
for control of expression via the lac repressor. When cloned
into the expression vector, an N-terminal His6 tag was
included for purification, followed by a Ser-Ala spacer and
a factor Xa protease recognition site (Ile-Glu-Gly-Arg) for
later removal of the His6 tag. The additional cysteine in the
hybrid domain (Cys 204) was also replaced with a serine as
described previously (Jensen et al. 2009). This change was
necessary to allow effective in vitro refolding of the protein
fragment.
Protein was double labelled with 15N and 13C by
growing cells in M9 medium containing 0.1 % (w/v)
Fig. 1 a Domain organisation of constructs FBN1e2cb1 and FBN1NE3,
discussed in this study, and their size in relation to the full-length
fibrillin molecule. b 950 MHz 1H-15N HSQC spectrum for FBN1e2cb1
in 95 % H2O/5 % D2O at pH 5.4 with 5 mM CaCl2. Peak assignments
are shown above their respective peaks, except where otherwise
indicated by lines. Small crosses indicate peaks that were too weak to
visualise in this spectrum at the contour level selected
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15NH4Cl and 0.5 % (w/v)
13C-glucose (Goss Scientific), in
the presence of 100 lg/ml ampicillin and 25 lg/ml kana-
mycin. 50 ml of starter culture, grown in unlabelled M9
medium at 37 C for *18 h, was used to inoculate 600 ml
of labelled M9 medium. Bacteria were grown until OD600
reached *0.8, at which point expression was induced with
isopropyl-b-D-thiogalactopyranoside (IPTG) at a final
concentration of 1 mM. Cells were then incubated at 28 C
for *20 h, harvested by centrifugation and frozen at
-80 C prior to protein purification.
The expressed fibrillin protein appeared to form insolu-
ble inclusion bodies, which did not dissolve in buffer con-
taining 6 M guanidine, and so to increase protein yield an
inclusion body extraction was carried out. The bacterial
pellet was thawed and resuspended in a lysis buffer of 25 %
(w/v) sucrose, 50 mM Tris–HCl pH 8.0, and 1 mM EDTA
(20 ml buffer per litre of culture). Lysozyme was also added
(2.5 mg per litre culture) to help break cell walls. Once
resuspended the cells were lysed by sonication with 5 bursts
of 30 s at 20 W (Jencons Ultrasonic Processor), swirling the
mixture between bursts to make sure that the temperature
did not increase locally. The lysate was then centrifuged at
12,000 rpm (JA-20 rotor) for 20 min. The resulting super-
natant was discarded and the pellet was resuspended in
inclusion body buffer 1 (25 ml per litre of culture), con-
taining 1 % (w/v) sodium deoxycholate, 200 mM NaCl,
2 mM EGTA, and 20 mM Tris–HCl pH 8.0. Resuspension
was assisted with repeated stirring and sonication. The
mixture was then centrifuged again at 12,000 rpm (JA-20
rotor) for 20 min and the supernatant discarded. The pellet
was resuspended in inclusion body buffer 2 (25 ml per litre
of culture), containing 0.25 % sodium deoxycholate, 1 mM
EGTA, and 20 mM Tris–HCl pH 8.0. Resuspension was
assisted with repeated stirring and sonication. The mixture
was centrifuged at 12,000 rpm (JA-20 rotor) for 20 min.
Resuspension in inclusion body buffer 2 was repeated three
times, or as many as necessary to remove the majority of
white membrane residue and give a pure brown pellet. The
inclusion body pellet was then dissolved in 8 M urea, with
0.1 mM NaN3, 1 mM EGTA, 50 mM dithiothreitol and
10 mM Tris–HCl pH 8.0, using a hand homogeniser to
break up the inclusion bodies. The resulting protein-urea
solution was then acidified and dialysed against 0.1 % (v/v)
trifluoroacetic acid (TFA). After dialysis, SDS-PAGE was
used to confirm the purity of the dissolved inclusion bodies.
Protein solution was then transferred directly into a refold
mix consisting of an aqueous solution of *0.2 mg/ml
reduced protein, 50 % (v/v) glycerol (to enhance protein
solubility), 100 mM Tris–HCl pH 8.3, 3 mM cysteine and
0.3 mM cystine, and 50 mM CaCl2, which was then left for
48 h at 4 C. After this period the refold mixture was
acidified to pH 2 with HCl, and dialysed against 0.1 % (v/v)
TFA overnight. Dialysate was centrifuged and filtered to
remove any precipitate, concentrated by ultrafiltration, fil-
tered again, and then purified by high performance liquid
chromatography (HPLC) using a C8 reverse phase column
(Rainin).
The His6 tag was cleaved off by incubation with factor Xa
(Novagen), carried out with a maximum protein concen-
tration of 1.5 mg/ml, with 30 mM MES-HCl pH 6, 100 mM
NaCl, 10 mM CaCl2, and 1 unit factor Xa per mg protein,
and incubated at 37 C overnight. Protein was further puri-
fied by cation exchange fast protein liquid chromatography
(FPLC) using a MonoS 5/50 GL column (GE Healthcare).
For these purifications the buffers used were 30 mM citrate
solution at pH 4, with 2 M NaCl added to the elution buffer.
After FPLC all proteins were acidified to*pH 2, filtered to
remove any precipitate, and desalted by further HPLC
purification before final lyophilisation. The final product
was analysed by SDS-PAGE in the presence or absence of
5 % (v/v) 2-mercaptoethanol for reduction of disulphide
bonds, as well as by electrospray ionisation mass spec-
trometry (observed mass = 18,820 Da).
NMR experiments for assignment were performed using
15N/13C double-labelled protein at a concentration of
1–1.5 mM in either 5 % D2O/95 % H2O (v/v) or 100 %
D2O, with 5 mM CaCl2 at pH 5.4. NMR experiments were
carried out at 25 C on three different spectrometers: a
home-built spectrometer with a 1H operating frequency of
950 MHz, a triple-resonance pulsed-field-gradient probe
and GE/Omega data acquisition system, a second home-
built spectrometer with a 1H operating frequency of
750 MHz, a triple-resonance pulsed-field-gradient probe
and GE/Omega data acquisition system, or a Bruker
Avance 500 MHz spectrometer with a Cryoplatform,
equipped with a TCI CryoProbe. Backbone assignments were
obtained using 3D HNCA, CBCANH, CBCA(CO)NH,
HNCO, HN(CA)CO and HBHA(CO)NH triple-resonance
experiments, and side-chain assignments were obtained
with 3D HCCH-TOCSY (collected in 100 % D2O), 3D
13C-edited NOESY-HSQC (collected in both 100 % D2O
and 5 % D2O/95 % H2O), and 2D
1H NOESY (collected in
100 % D2O) experiments. NMR data were processed using
NMRPipe (Delaglio et al. 1995) and analysed using
CcpNmr Analysis (Vranken et al. 2005).
Assignment and data deposition
The FBN1e2cb1 fragment expressed contains 177 amino
acids following factor Xa cleavage. Assignments were
obtained for 88 % of all 1H resonances, 81 % of 13C res-
onances, and 69 % of 15N resonances. More specifically,
94 % of backbone 1HN, 87 % of backbone 15N, 93 % of
Ha, 92 % of Hb, 95 % of Ca, 94 % of Cb and 93 % of C0
resonances were assigned. An annotated 1H-15N HSQC is
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shown in Fig. 1b. A significant number of residues gave
extremely weak peaks, which prevented complete back-
bone assignment. Side-chain assignment was also hindered,
to an extent, by weak or absent peaks, and also by strong
peaks obscuring other resonances in some regions of 3D
HCCH-TOCSY and 3D 13C-edited NOESY-HSQC spectra.
15N resonances from proline residues were not assigned.
Assignments have been published previously for a
fragment of the fibrillin N-terminus, including the fibrillin
unique N-terminal FUN domain, EGF1, EGF2 and EGF3
(FBN1NE3) (Yadin et al. 2012). The EGF2 and EGF3
domains of this protein fragment overlap with the fragment
assigned here (Fig. 1a), and comparison of the Ha, Hb, and
amide assignments for the two overlapping domains of
both fragments demonstrates similar peak positions for
many of the EGF2-EGF3 resonances (Fig. 2). This sup-
ports both domains adopting similar folds in the FBN1NE3
and FBN1e2cb1 constructs. However, significant changes in
peak position were seen for some selected residues, espe-
cially for residues corresponding to the C-terminal loop of
EGF3 (residues 171–178). In homologous EGF structures
this region is involved in inter-domain packing interactions
with a downstream domain (Downing et al. 1996; Jensen
et al. 2012; Lee et al. 2004; Smallridge et al. 2003). For
EGF3 this is the hyb1 domain, which is present in
FBN1e2cb1, but absent from FBN1NE3. In EGF and cbEGF
domains packing with the downstream domain is particu-
larly centred around a glycine-aromatic residue pair in the
C-terminal loop, and a Gly-Phe motif is found here in
fibrillin-1 EGF3 (residues 171–172). The Ha resonances of
Gly 171 exhibit a significant upfield shift in FBN1e2cb1
compared to FBN1NE3, which may be due to ring-current
effects from packing with an aromatic side chain, induced
by the presence of hyb1. The Ha resonance of Phe 172 on
the other hand exhibits a downfield shift when hyb1 is
present, which may also be influenced by packing
interactions.
The Hb protons of Asn 156 also demonstrate significant
upfield shifts from 2.16 and 2.19 in FBN1NE3 to 1.12 and
1.89 ppm in FBN1e2cb1, suggestive of packing above or
below the plane of an aromatic ring. While not at the
C-terminus of the EGF3 sequence, this asparagine is pre-
dicted from homology modelling to be on a loop that would
be close to the C-terminus of the EGF3 domain when
folded, and could be brought into contact with aromatic
residues at the C-terminus of EGF3 or in the hyb1 domain.
Generally the differences in EGF3 chemical shifts between
FBN1NE3 and FBN1e2cb1 strongly suggest domain interface
formation between EGF3 and hyb1 in FBN1e2cb1, which
has implications for the overall structure of the fibrillin
molecule, and may also affect the presentation of protein
interaction sites in this region.
The chemical shift assignments for fibrillin-1 EGF2-
EGF3-hyb1-cbEGF1 have been deposited in the BioMa-
gResBank (http://www.bmrb.wisc.edu) under the accession
number 19078.
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